News | October 14, 2024
Zydus and ICMR initiate a Phase 2 trial of Desidustat in patients with Sickle Cell Disease
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Subscribe To Our Newsletter & Stay Updated
